Drug Type CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 1 | CN | 08 Apr 2022 | |
CD19-positive B-cell Precursor acute lymphoblastic leukemia | Phase 1 | CN | 15 Aug 2021 | |
CD22-positive B-cell Precursor acute lymphoblastic leukemia | Phase 1 | CN | 15 Aug 2021 | |
Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | CN | 01 Apr 2020 |
NCT05206071 (EHA2022) Manual | Not Applicable | 26 | Fludarabine Phosphate+Cyclophosphamide+CAR19/22 (murinized CAR-T cells) | irrullyhhm(pcbwaouifk) = zeuepnqhwq bafnxufpkn (qkvckrxnwd ) View more | Positive | 12 May 2022 | |
Fludarabine Phosphate+Cyclophosphamide+CAR19/22 (humanized CAR-T cells) | irrullyhhm(pcbwaouifk) = jhlsqmspmx bafnxufpkn (qkvckrxnwd ) View more |